Evotec AG Given “Overweight” Rating at JPMorgan Chase & Co. (EVTC)
Evotec AG (NASDAQ:EVTC)‘s stock had its “overweight” rating restated by investment analysts at JPMorgan Chase & Co. in a note issued to investors on Wednesday. They currently have a $31.00 price target on the stock, up from their previous price target of $27.00. JPMorgan Chase & Co.’s price target suggests a potential upside of 38.21% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Stifel Nicolaus cut their price target on shares of Evotec AG from $28.00 to $27.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. Analysts at Goldman Sachs initiated coverage on shares of Evotec AG in a research note on Tuesday, July 8th. They set a “neutral” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Evotec AG presently has a consensus rating of “Buy” and an average target price of $27.33.
Evotec AG (NASDAQ:EVTC) traded up 1.87% on Wednesday, hitting $22.85. 161,355 shares of the company’s stock traded hands. Evotec AG has a one year low of $20.64 and a one year high of $26.33. The stock’s 50-day moving average is $23.15 and its 200-day moving average is $23.85. The company has a market cap of $1.797 billion and a price-to-earnings ratio of 25.69.
Evotec AG (NASDAQ:EVTC) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.01. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $94.40 million. During the same quarter in the previous year, the company posted $0.35 earnings per share. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts predict that Evotec AG will post $1.67 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Friday, September 5th. Investors of record on Monday, August 18th will be paid a dividend of $0.10 per share. This represents a $0.40 annualized dividend and a dividend yield of 1.78%. The ex-dividend date is Thursday, August 14th.
Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.